Guidewire Pacing and Pressure Assessment in TAVR: The SAFE-TAVI Study

Currently, the number of transcatheter aortic valve replacement (TAVR) procedures is increasing as it expands towards a lower-risk younger population. Therefore, continuous technological advancement is imperative to reduce post-procedural complications. The Food and Drug Administration (FDA) has approved the SavyWire, a preformed 0.035-gauge guidewire that can perform three essential functions: 1) it facilitates prosthesis transportation and placement; 2) it allows for continuous hemodynamic monitoring through a distal optical fiber sensor; and 3) it enables wire pacing through the left ventricle.

pacemaker marcapasos definitivo

The objective of the prospective multicenter SAFE-TAVI (SavvyWire Efficacy and Safety in Transcatheter Aortic Valve Implantation Procedures) Study was to assess the safety and efficacy of the SavyWire in TAVR with both balloon-expandable and self-expandable valves.

The primary endpoint (PEP) was rapid and effective pacing with a significant drop in pressure (reduction of systolic pressure below 60 mmHg). The secondary safety endpoint (SSE) was absence of guidewire-related major complications.

The analysis included 119 patients; the mean age was 82.2 ± 5.9 years, and 49.6% of subjects were women. The mean STS score was 3.85. All patients were treated using the transfemoral access. Balloon-expandable valves were used in 37.8% of cases, with predilation performed in 74.8% and postdilation in 11.8% of patients.

Read also: Use of IVL in Calcified Coronary Lesions in a Real World Population.

Regarding the PEP, 98.3% of patients showed a drop in systolic pressure below 60 mmHg, with a mean arterial systolic pressure during rapid pacing of 46.6±11.3 mmHg. The SSE was achieved in 99.2% of cases, with no mortality, stroke, guidewire kinking, or ventricular perforation events.

Conclusion

The results of this study demonstrate the safety and efficacy of the SavyWire during TAVR. This device may contribute to minimizing intervention during the procedure and improving clinical outcomes after TAVR implantation.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Safety and Efficacy of Transcatheter Aortic Valve Replacement With a Pressure Sensor and Pacing Guidewire SAFE-TAVI Trial.

Reference: Ander Regueiro, MD, PHD et al J Am Coll Cardiol Intv 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...